Foxx Development Holdings Inc. (NASDAQ: FOXX) disclosed in a Securities and Exchange Commission Form 4 filing that its Chief Technology Officer, James Liao, sold 9,716 shares of the company’s common stock on February 19, 2026. The shares were transacted at $4.61 apiece, generating total proceeds of $44,790. The filing indicates Liao now directly owns zero shares of Foxx Development.
Since that sale, Foxx Development’s share price has fallen to $4.24. The company’s stock has declined roughly 24% over the past six months, a trend the filing notes without attributing causes.
Separately, analysis from InvestingPro cited in company materials suggests that the stock may be trading below its Fair Value, placing FOXX on a list of potentially undervalued names. The company’s financial health was characterized as "WEAK" in that analysis, with additional ProTips available to subscribers of the service.
Governance updates
In other corporate developments, Foxx Development confirmed the election of Michelle Jie Shen to its board of directors. The company said it has entered into an offer letter and an indemnification agreement with Ms. Shen. Under the disclosed terms, she will receive an annual director fee of $60,000. The indemnification agreement is retroactive to her appointment date of December 22, 2025.
Foxx Development also issued a clarification about its 2025 Annual Meeting of Stockholders. The company corrected an earlier error in proxy materials regarding the virtual meeting site. The Annual Meeting will take place at the company’s offices in Irvine, California, and will also be accessible online. Stockholders who wish to attend virtually must register in advance through a Microsoft Forms link, per the company’s correction.
Context and implications
The Form 4 filing provides a clear record of the insider sale and the CTO’s current direct ownership position of zero shares. The company simultaneously disclosed board-level changes and procedural corrections for its stockholder meeting. The InvestingPro commentary included in the company’s disclosures highlights a dichotomy between a valuation argument of potential undervaluation and an assessment of weak financial health.
Where the filing and related disclosures do not provide further commentary, readers are left with the factual record of the transaction, the governance developments, and the company’s corrected meeting logistics.